Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
Pfizer Inc. won a court victory against Australia’s antitrust regulator over charges that it abused its market dominance in the blockbuster cholesterol drug Lipitor to cut out generic competition and keep prices high.
The Full Federal Court dismissed an appeal May 25 by Australian Competition and Consumer Commission (ACCC), which sought to overturn a trial court decision in favor of Pfizer. The ruling lets Pfizer off the hook, but the ACCC could win similar cases in the future because a change to Australia’s competition law in November makes it easier to prove abuse of dominance. The Pfizer charges were brought before then.
“The ACCC remains committed to pursuing cases involving anticompetitive conduct, particularly misuse of market power, because of the harm that can be caused to the competitive process and ultimately to consumers,” ACCC Chairman Rod Sims said in response to the ruling. “The ACCC is carefully considering the judgment.”
The ACCC instituted proceedings in February 2014 alleging Pfizer misused its position as a patent holder of Lipitor “to prevent or deter competition” from other suppliers selling the generic version. The ACCC alleged that Pfizer used bundled discounts for Lipitor in 2012 to lock in buyers just as its patent was expiring, creating a roadblock to generic competitors getting traction in the market.
Under Australia’s competition law at the time, the ACCC’s case turned on whether it could prove that Pfizer’s conduct was “for the purpose of substantially lessening competition in the market.” The lower court held in February 2015 that the ACCC failed to prove an anticompetitive purpose.
The Full Federal Court heard the ACCC’s appeal the following November. The court’s reasoning in upholding the lower court’s decision isn’t yet available.
The change in the law means that the ACCC need no longer prove what Pfizer’s purpose was in attempting to bring an abuse of dominance case. Now, the ACCC can point to market effects to show harm from an alleged abuse of dominance.
The ACCC rarely brought abuse actions under the old law, which Sims called “almost unusable” in press reports. Sims told an economic development conference in February that “misuse of market power and concerted practices will be key ACCC enforcement priorities in 2018.”
“As you would expect, the ACCC fought hard for these provisions, and we will be using them,” he said.
To contact the reporter on this story: Eleanor Tyler in Washington at email@example.com
To contact the editor responsible for this story: Fawn Johnson at firstname.lastname@example.org
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)